Cargando…
P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430937/ http://dx.doi.org/10.1097/01.HS9.0000971416.40088.99 |
| _version_ | 1785091079507279872 |
|---|---|
| author | Iyer, Swaminathan Jagadeesh, Deepa Domingo Domènech, Eva Benedetti, Fabio Rodriguez Izquierdo, Antonia Bouabdallah, Kamal Vitolo, Umberto Illidge, Tim Liu, Jingmin Knowles, Scott Horwitz, Steven |
| author_facet | Iyer, Swaminathan Jagadeesh, Deepa Domingo Domènech, Eva Benedetti, Fabio Rodriguez Izquierdo, Antonia Bouabdallah, Kamal Vitolo, Umberto Illidge, Tim Liu, Jingmin Knowles, Scott Horwitz, Steven |
| author_sort | Iyer, Swaminathan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430937 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309372023-08-17 P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032 Iyer, Swaminathan Jagadeesh, Deepa Domingo Domènech, Eva Benedetti, Fabio Rodriguez Izquierdo, Antonia Bouabdallah, Kamal Vitolo, Umberto Illidge, Tim Liu, Jingmin Knowles, Scott Horwitz, Steven Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430937/ http://dx.doi.org/10.1097/01.HS9.0000971416.40088.99 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Iyer, Swaminathan Jagadeesh, Deepa Domingo Domènech, Eva Benedetti, Fabio Rodriguez Izquierdo, Antonia Bouabdallah, Kamal Vitolo, Umberto Illidge, Tim Liu, Jingmin Knowles, Scott Horwitz, Steven P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032 |
| title | P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032 |
| title_full | P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032 |
| title_fullStr | P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032 |
| title_full_unstemmed | P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032 |
| title_short | P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032 |
| title_sort | p1130: frontline brentuximab vedotin and chp (a+chp) in patients with peripheral t-cell lymphoma with less than 10% cd30 expression: initial safety and efficacy results from the phase 2 study sgn35-032 |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430937/ http://dx.doi.org/10.1097/01.HS9.0000971416.40088.99 |
| work_keys_str_mv | AT iyerswaminathan p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT jagadeeshdeepa p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT domingodomenecheva p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT benedettifabio p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT rodriguezizquierdoantonia p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT bouabdallahkamal p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT vitoloumberto p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT illidgetim p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT liujingmin p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT knowlesscott p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 AT horwitzsteven p1130frontlinebrentuximabvedotinandchpachpinpatientswithperipheraltcelllymphomawithlessthan10cd30expressioninitialsafetyandefficacyresultsfromthephase2studysgn35032 |